MedTrace Logo

Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.

NCT07294430 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-19

No results posted yet for this study

Summary

OASIS-ImmunoPET is a monocentric pilot study evaluating antibody imaging to predict response to antibody-drug conjugate (ADC), an innovative cancer targeted therapy, and potentially replace tumor biopsy. It is addressed to patients with locally advanced or metastatic breast cancer who are eligible to receive the ADC Trastuzumab deruxtecan (T-DXd) according to local approval, and who are already enrolled in OASIS study (NCT pending).

Conditions

Interventions

PROCEDURE

Immuno-PET

Realization of an advanced molecular imaging exam to visualize the T-DXd target (HER2) expression throughout the body, at baseline and at treatment discontinuation. This procedure relies on the administration to the patient of a radioactive tracer \[89Zr\]-anti-HER2. This experimental imaging is associated to standard FDG-PET scans for tumor assessment.

Sponsors & Collaborators

  • Jules Bordet Institute

    collaborator OTHER

  • UNICANCER

    lead OTHER

Principal Investigators

  • Barbara Pistilli, MD, PhD · Gustave Roussy Cancer Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2028-12-31
Completion
2030-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07294430 on ClinicalTrials.gov